Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report

Advanced basal cell carcinoma may be treated with systemic therapies such as hedgehog pathway inhibitors or programmed cell death protein 1 inhibitors, namely cemiplimab. We report a case of a 70-year-old man with a nodulo-infiltrative advanced basal cell carcinoma over the right posterior neck and...

Full description

Saved in:
Bibliographic Details
Published in:SAGE open medical case reports 2023-01, Vol.11, p.2050313X231164248
Main Authors: Sarfaraz, Sidra, Hayes, Robert C, Hunt, Anne-Marie
Format: Article
Language:English
Subjects:
Immunotherapy
JCMS Case Report
Monoclonal antibodies
Skin cancer
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advanced basal cell carcinoma may be treated with systemic therapies such as hedgehog pathway inhibitors or programmed cell death protein 1 inhibitors, namely cemiplimab. We report a case of a 70-year-old man with a nodulo-infiltrative advanced basal cell carcinoma over the right posterior neck and scapula. The patient had a partial response to the hedgehog pathway inhibitor, vismodegib. The tumour progressed, and the patient was switched from vismodegib to radiotherapy combined with cemiplimab, which led to a significant reduction in pain, bleeding, and tumour size. A combined treatment approach with radiotherapy and cemiplimab may be beneficial for advanced basal cell carcinoma cases that progress after treatment with hedgehog pathway inhibitors.
ISSN:2050-313X
2050-313X
DOI:10.1177/2050313X231164248